Genocea Biosciences (GNCA) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- Reddit leads social media platforms in revenue growth per user
- L3Harris CEO steps down amid conduct review, shares drop
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Six dead in 'stampede-like' incident at India temple, ANI says
Genocea Reports First Quarter 2015 Financial Results
May 7, 2015 8:00 AM EDTPhase 2 top-line data for GEN-003 for the treatment of genital herpes expected this quarter
$52 million financing completed in March 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the first quarter ended March 31, 2015.
"2015 is an important year for Genocea with significant clinical data readouts upcoming for both our lead programs. Top-line Phase 2 data for GEN-003, for the treatment of genital herpes, is expected this... More
